Abstract Dapagliflozin is an oral hypoglycemic agent. It is a medication used to treat type 2 diabetes. It is a selective sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor that inhibits glucose reabsorption and induces glucosuria. Dapagliflozin is used with pioglitazone, saxagliptin, metformin, sitagliptin, and glimepiride.
Considering the therapeutic significance of dapagliflozin, the reliability of its application is dependent on bioanalytical data; therefore, in this review, we focus on critical compilation and the evaluation of analytical methods for the analysis of dapagliflozin and its available combinations.
This review focuses on previously reported analytical techniques for determining dapagliflozin in biological samples and pharmaceutical formulations using a combination of sitagliptin, saxagliptin, metformin, pioglitazone, and glimepiride. Therefore, this attempt of critical compilation of data will help to design proper analytical methods for the analysis of dapagliflozin in combination with its dosage form and biological fluid.
The current review article may be successfully used to perform future analytical research for dapagliflozin’s estimate.
Keywords Dapagliflozin, Analytical methods , Diabetes mellitus type 2.